GSK's Cervarix Two-Dose Vaccine Schedule Approved in China
27 May 2022 - 4:40PM
Dow Jones News
By Jaime Llinares Taboada
GSK PLC said Friday that China has approved a two-dose schedule
for its Cervarix vaccine for girls aged nine to 14.
The healthcare company said that the vaccine is against certain
types of cancer-causing human papillomavirus. In 2020, there were
110,000 new cases of cervical cancer and 59,000 deaths due to the
disease in China, it said.
The authorization of the two-dose regime by the Chinese
regulator adds to approvals in around 100 countries. The three-dose
schedule remains on the label for girls and women aged 15-45 years
in China, GSK said.
Write to Jaime Llinares Taboada at jaime.llinares@wsj.com;
@JaimeLlinaresT
(END) Dow Jones Newswires
May 27, 2022 02:25 ET (06:25 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Gsk (LSE:GSK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Gsk (LSE:GSK)
Historical Stock Chart
From Apr 2023 to Apr 2024
